Luminal Arc’s work spans scientific, operational, and organizational challenges across CGT and biologics. These examples illustrate how the advisory posture shows up in practice.

• Defined the platform identity and operational architecture for a novel CGT technology, helping the founder translate scientific innovation into a viable platform strategy with clear sequencing and market positioning.

• Established cultural values, ways of working, and a mission statement for an emerging CGT company, aligning scientific ambition with organizational aptitude.

• Created an operational and CDMO management framework that supported strategic decisions with scientific rigor, transparency, and the right level of operational readiness.

• Designed an end to end CMC operational roadmap from preclinical through BLA, aligning scientific, regulatory, and operational decisions into a coherent, sequenced plan tied to program inflection points.

• Sequenced early operational decisions for a seed stage company, guiding assay development, material generation, and partnership strategy to prevent premature commitments and protect optionality.

• Assessed how a new CGT capability could be integrated into an existing biologics CDMO, identifying the market segment, staged expansion strategy, operational gaps, and the narrative required to layer a new modality onto an established structure.